Expert Review of Pharmacoeconomics and Outcomes Research

, volume 21 , issue 4 , pages 527-540

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Brian Godman ^{1, 2, 3, 4}

Andrew Hill ⁵

Steven Simoens ⁶

Gisbert W Selke ⁷

Iva Selke Krulichová ⁸

Carolina Zampirolli Dias ^{9, 10}

Antony Paul Martin ^{11, 12}

Wija Oortwijn ¹³

Angela Timoney ^{2, 14}

Lars L. Gustafsson ¹

Luka Voncina ¹⁵

Hye-Young Kwon ^{2, 16}

Jolanta Gulbinovič ¹⁷

Dzintars Gotham ¹⁸

Janet Wale ¹⁹

Wânia Cristina Da Silva ^{9, 20}

Tomasz Bochenek ²¹

Eleonora Allocati ²²

Amanj I.B. Kurdi ^{2, 3, 23}

Olayinka O Ogunleye ^{24, 25}

Johanna M. Meyer ³

Iris Hoxha ²⁶

Admir Malaj ²⁷

Christian Hierländer ²⁸

Robert Sauermann ²⁸

Wouter Hamelinck ²⁹

Guenka Petrova ³⁰

Ott Laius ³¹

Irene Langner ⁷

John Yfantopoulos ³²

Roberta Joppi ³³

Arianit Jakupi ³⁴

Ieva Greičiūtė Kuprijanov ³⁵

Patricia Vella Bonanno ²

Jf (hans) Piepenbrink ³⁶

Vincent de Valk ³⁶

Magdalene Wladysiuk ³⁷

Vanda Markovic Pekovic ³⁸

Ileana Mardare ³⁹

Jurij Fürst ⁴⁰

Dominik Tomek ⁴¹

Mercè Obach ⁴²

Corinne Zara ⁴²

C. Pontes ^{42, 43}

Stuart Mctaggart ⁴⁴

Tracey-Lea Laba ⁴⁵

Øyvind Melien ⁴⁶

Durhane Wong Rieger ⁴⁷

SeungJin Bae ⁴⁸

R.A. Hill ⁴⁹

Hide authors affiliations Show authors affiliations: 49 affiliations

Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden

Karolinska Institute

Karolinska University Hospital

Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK |

Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa |

⁴

School of Pharmaceutical Sciences, universiti Sains Malaysia, Penang, Malaysia |

⁵

Institute of Translational Medicine, University of Liverpool, UK |

⁶

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium |

⁷

Wissenschaftliches Institut der AOK (WIDO), Berlin, Germany |

⁸

Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Hradec, Králové, Czech Republic

Charles University

University of Hradec Králové

⁹

Faculty of Pharmacy, Postgraduate Program in Medicines and Pharmaceutical Services, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil |

¹⁰

SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil |

¹¹

Faculty of Health and Life Sciences, Liverpool, UK |

¹²

QC Medica, Sim Balk Lane, York UK |

¹³

Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands |

¹⁴

NHS Lothian, Edinburgh, UK |

¹⁵

Faculty of Health Studies, Rijeka, Croatia |

¹⁶

Division of Biology & Public Health, Mokwon University, Daejeon, Korea |

¹⁷

Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania |

¹⁸

Independent Researcher, Boston, MA, United States |

¹⁹

Independent Consumer Advocate, Brunswick, Victoria, Australia |

²⁰

Data and Knowledge Integration Center for Health(CIDACS), Fundação Oswaldo Cruz (FIOCRUZ)/ Salvador, Bahia, Brazil |

²¹

Department of Nutrition and Drug Research, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland |

²²

Istituto Di Ricerche Farmacologiche ‘Mario Negri’ IRCCS, Milan, Italy

Istituti di Ricovero e Cura a Carattere Scientifico

Mario Negri Institute for Pharmacological Research

²³

Department of pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq |

²⁴

Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria |

²⁵

Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria |

²⁶

Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania |

²⁷

University of Medicine, Tirana, Albania |

²⁸

Department of Pharmaceutical Affairs, Federation of Social Insurances, Vienna, Austria |

²⁹

Statistics Department, Bruxelles, Belgium |

³⁰

Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria |

³¹

State Agency of Medicines, Tartu, Estonia |

³²

School of National and Kapodistrian University of Athens Athens Greece |

³³

Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona, Verona, Italy |

³⁴

Faculty of Pharmacy, UBT – Higher Education Institution, Prishtina, Kosovo |

³⁵

Department of Pharmacy, Ministry of Health of the Republic of Lithuania, Vilnius, Lithuania |

³⁶

National Health Care Institute (ZIN), XH, Diemen, Netherlands |

³⁷

HTA Consulting, Cracow, Poland |

³⁸

Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina |

³⁹

Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, Bucharest, Romania |

⁴⁰

Health Insurance Institute, Ljubljana, Slovenia |

⁴¹

Faculty of Medicine, Slovak Medical University in Bratislava, Bratislava, Slovakia |

⁴²

Drug Department, Catalan Health Service, Catalan Health Service, Barcelona, Spain |

⁴³

Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain |

⁴⁴

Public Health Scotland, Edinburgh, UK |

⁴⁵

Centre for Health Economics Research and Evaluation, University of Technology Sydney, Broadway, Sydney, NSW |

⁴⁶

Reviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, Norway |

⁴⁷

Health Data Science, Institute of Population Health, Liverpool, Canadian Organization for Rare Disorders, Toronto, Ontario, Canada |

⁴⁸

College of Pharmacy, Ewha Woman’s University, Seoul, South Korea |

⁴⁹

Health Data Science, Institute of Population Health Liverpool Reviews and Implementation Group, Whelan Building, University of Liverpool, Liverpool, UK |

Publication type: Journal Article

Publication date: 2021-03-11

Taylor & Francis

Expert Review of Pharmacoeconomics and Outcomes Research

scimago Q2

wos Q3

SJR: 0.585

CiteScore: 3.8

Impact factor: 1.5

ISSN: 14737167, 17448379

DOI: 10.1080/14737167.2021.1884546

Copy DOI

PubMed ID: 33535841

General Medicine

Pharmacology (medical)

Health Policy

Found

1 citation

Lum Loveline

26 publications, 602 citations

h-index: 10

Top-30

Journals

	2 4 6 8 10 12
Frontiers in Pharmacology	Frontiers in Pharmacology, 11, 20.75% Frontiers in Pharmacology 11 publications, 20.75%
Expert Review of Pharmacoeconomics and Outcomes Research	Expert Review of Pharmacoeconomics and Outcomes Research, 4, 7.55% Expert Review of Pharmacoeconomics and Outcomes Research 4 publications, 7.55%
Vaccines	Vaccines, 3, 5.66% Vaccines 3 publications, 5.66%
BMJ Open	BMJ Open, 3, 5.66% BMJ Open 3 publications, 5.66%
PharmacoEconomics	PharmacoEconomics, 2, 3.77% PharmacoEconomics 2 publications, 3.77%
ESMO Open	ESMO Open, 2, 3.77% ESMO Open 2 publications, 3.77%
BioDrugs	BioDrugs, 2, 3.77% BioDrugs 2 publications, 3.77%
Value in Health	Value in Health, 2, 3.77% Value in Health 2 publications, 3.77%
BMC Public Health	BMC Public Health, 1, 1.89% BMC Public Health 1 publication, 1.89%
Current Medical Research and Opinion	Current Medical Research and Opinion, 1, 1.89% Current Medical Research and Opinion 1 publication, 1.89%
Life	Life, 1, 1.89% Life 1 publication, 1.89%
Diabetes Therapy	Diabetes Therapy, 1, 1.89% Diabetes Therapy 1 publication, 1.89%
Value in Health Regional Issues	Value in Health Regional Issues, 1, 1.89% Value in Health Regional Issues 1 publication, 1.89%
Social Science and Medicine	Social Science and Medicine, 1, 1.89% Social Science and Medicine 1 publication, 1.89%
Drug Discovery Today	Drug Discovery Today, 1, 1.89% Drug Discovery Today 1 publication, 1.89%
Cost Effectiveness and Resource Allocation	Cost Effectiveness and Resource Allocation, 1, 1.89% Cost Effectiveness and Resource Allocation 1 publication, 1.89%
Applied Health Economics and Health Policy	Applied Health Economics and Health Policy, 1, 1.89% Applied Health Economics and Health Policy 1 publication, 1.89%
Health Policy and Technology	Health Policy and Technology, 1, 1.89% Health Policy and Technology 1 publication, 1.89%
Cancers	Cancers, 1, 1.89% Cancers 1 publication, 1.89%
Journal of Multidisciplinary Healthcare	Journal of Multidisciplinary Healthcare, 1, 1.89% Journal of Multidisciplinary Healthcare 1 publication, 1.89%
Internal Medicine Journal	Internal Medicine Journal, 1, 1.89% Internal Medicine Journal 1 publication, 1.89%
Advances in Human Biology	Advances in Human Biology, 1, 1.89% Advances in Human Biology 1 publication, 1.89%
Saudi Pharmaceutical Journal	Saudi Pharmaceutical Journal, 1, 1.89% Saudi Pharmaceutical Journal 1 publication, 1.89%
PLoS ONE	PLoS ONE, 1, 1.89% PLoS ONE 1 publication, 1.89%
Journal of Pharmaceutical Policy and Practice	Journal of Pharmaceutical Policy and Practice, 1, 1.89% Journal of Pharmaceutical Policy and Practice 1 publication, 1.89%
European Journal of Haematology	European Journal of Haematology, 1, 1.89% European Journal of Haematology 1 publication, 1.89%
Global Health Research and Policy	Global Health Research and Policy, 1, 1.89% Global Health Research and Policy 1 publication, 1.89%
European Journal of Health Economics	European Journal of Health Economics, 1, 1.89% European Journal of Health Economics 1 publication, 1.89%
Clinical Therapeutics	Clinical Therapeutics, 1, 1.89% Clinical Therapeutics 1 publication, 1.89%
	2 4 6 8 10 12

Publishers

	2 4 6 8 10 12
Frontiers Media S.A.	Frontiers Media S.A., 11, 20.75% Frontiers Media S.A. 11 publications, 20.75%
Springer Nature	Springer Nature, 10, 18.87% Springer Nature 10 publications, 18.87%
Elsevier	Elsevier, 10, 18.87% Elsevier 10 publications, 18.87%
Taylor & Francis	Taylor & Francis, 7, 13.21% Taylor & Francis 7 publications, 13.21%
MDPI	MDPI, 6, 11.32% MDPI 6 publications, 11.32%
BMJ	BMJ, 3, 5.66% BMJ 3 publications, 5.66%
Wiley	Wiley, 2, 3.77% Wiley 2 publications, 3.77%
Medknow	Medknow, 1, 1.89% Medknow 1 publication, 1.89%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 1.89% Public Library of Science (PLoS) 1 publication, 1.89%
Cambridge University Press	Cambridge University Press, 1, 1.89% Cambridge University Press 1 publication, 1.89%
	2 4 6 8 10 12

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Godman B. et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications // Expert Review of Pharmacoeconomics and Outcomes Research. 2021. Vol. 21. No. 4. pp. 527-540.

GOST all authors (up to 50) Copy

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1080/14737167.2021.1884546

UR - https://doi.org/10.1080/14737167.2021.1884546

TI - Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

AU - Godman, Brian

AU - Hill, Andrew

AU - Simoens, Steven

AU - Selke, Gisbert W

AU - Selke Krulichová, Iva

AU - Zampirolli Dias, Carolina

AU - Martin, Antony Paul

AU - Oortwijn, Wija

AU - Timoney, Angela

AU - Gustafsson, Lars L.

AU - Voncina, Luka

AU - Kwon, Hye-Young

AU - Gulbinovič, Jolanta

AU - Gotham, Dzintars

AU - Wale, Janet

AU - Cristina Da Silva, Wânia

AU - Bochenek, Tomasz

AU - Allocati, Eleonora

AU - Kurdi, Amanj I.B.

AU - Ogunleye, Olayinka O

AU - Meyer, Johanna M.

AU - Hoxha, Iris

AU - Malaj, Admir

AU - Hierländer, Christian

AU - Sauermann, Robert

AU - Hamelinck, Wouter

AU - Petrova, Guenka

AU - Laius, Ott

AU - Langner, Irene

AU - Yfantopoulos, John

AU - Joppi, Roberta

AU - Jakupi, Arianit

AU - Greičiūtė Kuprijanov, Ieva

AU - Vella Bonanno, Patricia

AU - Piepenbrink, Jf (hans)

AU - de Valk, Vincent

AU - Wladysiuk, Magdalene

AU - Markovic Pekovic, Vanda

AU - Mardare, Ileana

AU - Fürst, Jurij

AU - Tomek, Dominik

AU - Obach, Mercè

AU - Zara, Corinne

AU - Pontes, C.

AU - Mctaggart, Stuart

AU - Laba, Tracey-Lea

AU - Melien, Øyvind

AU - Wong Rieger, Durhane

AU - Bae, SeungJin

AU - Hill, R.A.

PY - 2021

DA - 2021/03/11

PB - Taylor & Francis

SP - 527-540

IS - 4

VL - 21

PMID - 33535841

SN - 1473-7167

SN - 1744-8379

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2021_Godman,

author = {Brian Godman and Andrew Hill and Steven Simoens and Gisbert W Selke and Iva Selke Krulichová and Carolina Zampirolli Dias and Antony Paul Martin and Wija Oortwijn and Angela Timoney and Lars L. Gustafsson and Luka Voncina and Hye-Young Kwon and Jolanta Gulbinovič and Dzintars Gotham and Janet Wale and Wânia Cristina Da Silva and Tomasz Bochenek and Eleonora Allocati and Amanj I.B. Kurdi and Olayinka O Ogunleye and Johanna M. Meyer and Iris Hoxha and Admir Malaj and Christian Hierländer and Robert Sauermann and Wouter Hamelinck and Guenka Petrova and Ott Laius and Irene Langner and John Yfantopoulos and Roberta Joppi and Arianit Jakupi and Ieva Greičiūtė Kuprijanov and Patricia Vella Bonanno and Jf (hans) Piepenbrink and Vincent de Valk and Magdalene Wladysiuk and Vanda Markovic Pekovic and Ileana Mardare and Jurij Fürst and Dominik Tomek and Mercè Obach and Corinne Zara and C. Pontes and Stuart Mctaggart and Tracey-Lea Laba and Øyvind Melien and Durhane Wong Rieger and SeungJin Bae and R.A. Hill and others},

title = {Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications},

journal = {Expert Review of Pharmacoeconomics and Outcomes Research},

year = {2021},

volume = {21},

publisher = {Taylor & Francis},

month = {mar},

url = {https://doi.org/10.1080/14737167.2021.1884546},

number = {4},

pages = {527--540},

doi = {10.1080/14737167.2021.1884546}

}

MLA

Cite this

MLA Copy

Godman, Brian, et al. “Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 21, no. 4, Mar. 2021, pp. 527-540. https://doi.org/10.1080/14737167.2021.1884546.

Publisher

Taylor & Francis

Journal

Expert Review of Pharmacoeconomics and Outcomes Research

scimago Q2

wos Q3

SJR

0.585

CiteScore

3.8

Impact factor

1.5

ISSN

14737167 (Print)

17448379 (Electronic)